Johnson & JohnsonJNJEarnings & Financial Report
Johnson & Johnson (J&J) is an American multinational pharmaceutical, biotechnology, and medical technologies corporation headquartered in New Brunswick, New Jersey, and publicly traded on the New York Stock Exchange. Its common stock is a component of the Dow Jones Industrial Average, and the company is ranked No. 48 on the 2025 Fortune 500 list of the largest United States corporations. In 2025, the company was ranked 42th in the Forbes Global 2000.
JNJ Q4 2025 Key Financial Metrics
売上高
$24.6B
粗利益
$16.6B
営業利益
N/A
純利益
$5.1B
粗利益率
67.6%
営業利益率
N/A
純利益率
20.8%
前年比成長
9.1%
EPS
$2.08
資金フロー
Johnson & Johnson Q4 2025 Financial Summary
Johnson & Johnson reported revenue of $24.6B for Q4 2025, with a net profit of $5.1B (20.8% margin). Cost of goods sold was $8.0B, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $24.6B |
|---|---|
| Net Profit | $5.1B |
| Gross Margin | 67.6% |
| Operating Margin | N/A |
| Report Period | Q4 2025 |
Johnson & Johnson Annual Revenue by Year
Johnson & Johnson annual revenue history includes year-by-year totals (for example, 2025 revenue was $94.2B).
| Year | Annual Revenue |
|---|---|
| 2025 | $94.2B |
| 2024 | $88.8B |
| 2023 | $91.6B |
| 2022 | $94.7B |
損益計算書
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 売上高 | $21.38B | $22.45B | $22.47B | $22.52B | $21.89B | $23.74B | $23.99B | $24.56B |
| 前年比成長 | 7.2% | -9.3% | -12.0% | 5.5% | 2.4% | 5.8% | 6.8% | 9.1% |
貸借対照表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 総資産 | $171.97B | $181.09B | $178.29B | $180.10B | $193.67B | $193.39B | $192.82B | $199.21B |
| 総負債 | $101.95B | $109.55B | $108.13B | $108.61B | $115.56B | $114.92B | $113.54B | $117.67B |
| 株主資本 | $70.02B | $71.54B | $70.16B | $71.49B | $78.11B | $78.47B | $79.28B | $81.54B |
キャッシュフロー
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 営業CF | $3.66B | $5.63B | $7.99B | $6.98B | $4.17B | $3.88B | $9.17B | $7.31B |
Other Health Care Companies
BMY
Bristol Myers Squibb
売上高
$12.5B
純利益
$1.1B
LLY
Lilly (Eli)
売上高
$19.3B
純利益
$6.6B
MRK
Merck & Co.
売上高
$17.3B
純利益
$5.8B
PFE
Pfizer
売上高
$16.7B
純利益
$3.5B
VTRS
Viatris
売上高
$3.7B
純利益
N/A
ZTS
Zoetis
売上高
$2.4B
純利益
$603.0M
ABT
Abbott Laboratories
売上高
$11.4B
純利益
$1.6B
ABBV
AbbVie
売上高
$15.8B
純利益
$186.0M
A
Agilent Technologies
売上高
$1.9B
純利益
$434.0M
ALGN
Align Technology
売上高
$995.7M
純利益
$56.8M